


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8373812/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Laboratory Investigation, 2022, 102, 185-193.	3.7	8
2	Tight junction protein 1 promotes vasculature remodeling via regulating USP2/TWIST1 in bladder cancer. Oncogene, 2022, 41, 502-514.	5.9	10
3	Transcranial focused ultrasound stimulation reduces vasogenic edema after middle cerebral artery occlusion in mice. Neural Regeneration Research, 2022, 17, 2058.	3.0	14
4	Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma. Translational Oncology, 2022, 18, 101368.	3.7	2
5	MODL-29. Molecular Landscape of a comprehensive panel of pediatric brain cancer Patient-derived orthotopic xenograft (PDOX) models inform unique targets for drug responsiveness. Neuro-Oncology, 2022, 24, i175-i175.	1.2	0
6	Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion. Advanced Science, 2021, 8, e2101923.	11.2	11
7	Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. Cancer Research, 2020, 80, 5393-5407.	0.9	38
8	Methylation of the Promoter Region of the Tight Junction Protein-1 by DNMT1 Induces EMT-like Features in Multiple Myeloma. Molecular Therapy - Oncolytics, 2020, 19, 197-207.	4.4	6
9	ISL2 modulates angiogenesis through transcriptional regulation of ANGPT2 to promote cell proliferation and malignant transformation in oligodendroglioma. Oncogene, 2020, 39, 5964-5978.	5.9	16
10	Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors. Cancer Letters, 2020, 493, 197-206.	7.2	6
11	Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma. Cancers, 2020, 12, 1478.	3.7	21
12	Astrocytic trans-Differentiation Completes a Multicellular Paracrine Feedback Loop Required for Medulloblastoma Tumor Growth. Cell, 2020, 180, 502-520.e19.	28.9	99
13	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports, 2019, 29, 1675-1689.e9.	6.4	103
14	Transcriptional repressor REST drives lineage stage–specific chromatin compaction at <i>Ptch1</i> and increases AKT activation in a mouse model of medulloblastoma. Science Signaling, 2019, 12, .	3.6	19
15	IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, ii93-ii93.	1.2	1
16	Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models. Clinical Cancer Research, 2018, 24, 2159-2170.	7.0	24
17	Involvement of acid-sensing ion channel 1a in gastric carcinoma cell migration and invasion. Acta Biochimica Et Biophysica Sinica, 2018, 50, 440-446.	2.0	21
18	HGG-01. RADIATION INCREASES PRE-CLINICAL EFFICACY OF OLIG2 INHIBITOR CT-179 IN PEDIATRIC GBM. Neuro-Oncology, 2018, 20, i89-i89.	1.2	0

Lin Qi

#	Article	IF	CITATIONS
19	MBRS-62. REPRESSIVE CHROMATIN REMODELERS IN SHH-DRIVEN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i141-i141.	1.2	0
20	Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Science Signaling, 2018, 11, .	3.6	59
21	EPEN-13. NOVEL LSD-1 INHIBITOR VALIDATION IN NEWLY ESTABLISHED PFA EPENDYMOMA PATIENT-DERIVED ORTHOTOPIC XENOGRAFT (PDOX) MODELS. Neuro-Oncology, 2018, 20, i76-i76.	1.2	0
22	IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma. PLoS ONE, 2018, 13, e0193565.	2.5	18
23	Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors Journal of Clinical Oncology, 2018, 36, 10551-10551.	1.6	1
24	Live kinase B1 maintains CD34+CD38â^' AML cell proliferation and self-renewal. Molecular and Cellular Biochemistry, 2017, 434, 25-32.	3.1	1
25	The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. Cancer Letters, 2017, 400, 61-68.	7.2	37
26	Xenotransplantation of pediatric low grade gliomas confirms the enrichment of <i>BRAF</i> V600E mutation and preservation of <i>CDKN2A</i> deletion in a novel orthotopic xenograft mouse model of progressive pleomorphic xanthoastrocytoma. Oncotarget, 2017, 8, 87455-87471.	1.8	21
27	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell, 2016, 29, 639-652.	16.8	85
28	Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students. Journal of Neurochemistry, 2016, 138, 785-805.	3.9	244
29	Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma. Journal of Neuro-Oncology, 2016, 128, 47-56.	2.9	13
30	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma. Cancer Cell, 2016, 29, 311-323.	16.8	204
31	HMGB1 Promotes Mitochondrial Dysfunction–Triggered Striatal Neurodegeneration via Autophagy and Apoptosis Activation. PLoS ONE, 2015, 10, e0142901.	2.5	27
32	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	30.7	473
33	Expression of acid-sensing ion channels in nucleus pulposus cells of the human intervertebral disk is regulated by non-steroid anti-inflammatory drugs. Acta Biochimica Et Biophysica Sinica, 2014, 46, 774-781.	2.0	18
34	A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children. Neuro-Oncology, 2014, 16, 787-799.	1.2	15
35	Isoquinoline Alkaloids from Corydalis impatiens. Chemistry of Natural Compounds, 2013, 49, 187-189.	0.8	20